Tesamorelin dosing in research protocols: what the published trials actually used

Tesamorelin’s published clinical-trial dose is 2 mg administered subcutaneously once daily. That dose was set in the early phase-2 dose-finding work and carried through both phase-3 trials and every subsequent academic study. Understanding why that specific dose was chosen — and where the dose-response literature shows deviations matter — is the foundation of any research-protocol design.

Why 2 mg, why once daily, why subcutaneous

Three pharmacology considerations converged on the 2 mg / once-daily / subcutaneous protocol used across the phase-3 program:

• The 2 mg dose saturates the receptor binding without exceeding physiological IGF-1. Phase-2 dose-finding work compared 1 mg, 2 mg, and 4 mg daily doses across 12-week treatment arms. The 2 mg arm produced a plasma IGF-1 elevation into the upper end of the age-adjusted normal range and held that elevation across the dosing period. The 4 mg arm did not produce proportionally greater IGF-1 elevation, suggesting the GHRH receptor signal was at or near saturation at 2 mg. Higher doses increased adverse events without improving the endpoint.
• Once-daily mirrors the pharmacokinetics. With a plasma half-life of ~30 minutes, the Tesamorelin signal at the pituitary lasts a few hours. Once-daily dosing produces a single pulse of GHRH receptor activation per 24 hours, which approximates the natural diurnal pattern of GHRH release. Twice-daily dosing was investigated in earlier phase-1 work but did not improve the downstream IGF-1 plateau enough to justify the doubled injection burden.
• Subcutaneous administration is the standard for the molecule’s plasma kinetics. Intravenous administration produces a sharper plasma-concentration spike but does not extend the duration of receptor activation; subcutaneous administration produces a smoother absorption curve that better matches the receptor-binding profile.

The dose-response literature

The clearest dose-response data comes from the phase-2 dose-finding study and the subsequent phase-3 trials [1]. The relevant data points:

• 1 mg daily subcutaneous. Produces submaximal IGF-1 elevation. Visceral-adipose tissue reduction at 26 weeks is approximately half of what the 2 mg arm produces. Not used in the registration trials.
• 2 mg daily subcutaneous. The standard protocol across all phase-3 work. Plasma IGF-1 plateaus at approximately 1.5-2× baseline (still within age-adjusted normal range). Visceral-adipose tissue reduction averages 15-18% over 26 weeks across the two phase-3 trials.
• 4 mg daily subcutaneous. Investigated in early phase-2 work. IGF-1 elevation is comparable to the 2 mg arm — the receptor signal is saturated. Adverse-event incidence (fluid retention, arthralgia, glucose tolerance changes) is materially higher than at 2 mg. Not used in the registration trials.

The dose-response curve is therefore non-linear and saturates around 2 mg. Doubling the dose does not double the IGF-1 elevation or the visceral-adipose effect, but it does increase the adverse-event burden roughly proportionally to plasma exposure.

Research-protocol design considerations

For independent research investigating the published Tesamorelin pharmacology, the 2 mg daily subcutaneous protocol is the natural reference. Deviation from that protocol should be tied to a specific mechanistic question the research is asking:

• Pharmacokinetic-comparison protocols sometimes use a single 2 mg dose followed by serial plasma sampling. The IGF-1 response is detectable at 24 hours, peaks around 48-72 hours, and returns to baseline within 7-14 days.
• Time-course protocols use 2 mg daily for variable durations (4 weeks, 12 weeks, 26 weeks, 52 weeks) to map the depot-effect kinetics. The phase-3 trials established the 26-week endpoint as the standard.
• Dose-escalation protocols are rare in independent research because the published phase-2 work has already characterised the saturation curve. Investigating doses above 2 mg in a research context generally requires a specific receptor-pharmacology question (e.g., super-physiological IGF-1 effect characterisation).

Single-dose acute pharmacology

Independent of the chronic-protocol literature, the acute single-dose Tesamorelin pharmacology is also well-characterised. A single 2 mg subcutaneous dose produces:

• Detectable plasma Tesamorelin within ~15 minutes; peak plasma concentration at ~30-60 minutes.
• GH release peaks at ~30-90 minutes post-injection (the typical GHRH-stimulus response timing).
• Plasma Tesamorelin is below the limit of detection by ~6-8 hours post-injection.
• IGF-1 elevation begins within 24 hours, peaks at 48-72 hours, and decays over 7-14 days.

UAE research-supply note

Tesamorelin is supplied in the UAE as lyophilised research-grade powder, most commonly in 10 mg vials. A 10 mg vial reconstituted in 1 mL bacteriostatic water produces 10 mg/mL; the 2 mg daily research dose is then 0.2 mL drawn on a U-100 insulin syringe. The free reconstitution calculator handles the unit conversion for non-standard reconstitution volumes. The storage and reconstitution guide covers the protocol in more depth.

Further reading

• [1] Spooner & Olin — Ann Pharmacother 2012. Tesamorelin phase-3 visceral-adipose data summary, including the 2 mg/day dose rationale.
• [2] Stanley et al. — JAMA 2014. Tesamorelin NAFLD extension RCT (also at 2 mg daily SC).
• Tesamorelin parent overview.
• Tesamorelin vs CJC-1295 — focused comparison.
• Tesamorelin side effects and tolerability.
• Tesamorelin storage and reconstitution.

Last reviewed 2 June 2026. Editorial inbox: info@uaewellnesslab.com.